Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data
Close

Genmab AS (GMAB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Genmab AS's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
38.93 +0.67    +1.75%
06/02 - Closed. Currency in USD ( Disclaimer )
After Hours
38.93
-0.00
-0.00%
21:51:26 - Real-time Data
  • Volume: 485,983
  • Bid/Ask: 38.82 / 39.24
  • Day's Range: 38.49 - 39.05
Type:  Equity
Market:  United States
Genmab AS 38.93 +0.67 +1.75%

GMAB Balance Sheet

 
Assess the latest Genmab AS balance sheet. Review the company's financial position, assess their current assets, liabilities and shareholder equity across the most recent periods (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2022
30/09
2022
30/06
2022
31/03
2021
31/12
Total Current Assets 28739 25491 23175 22736
Cash and Short Term Investments 23788 21615 19988 19338
Cash - - - -
Cash & Equivalents 10377 9816 9071 8957
Short Term Investments 13411 11799 10917 10381
Total Receivables, Net 4951 3876 3187 3398
Accounts Receivables - Trade, Net 4951 3876 2846 3367
Total Inventory - - - -
Prepaid Expenses - - - -
Other Current Assets, Total - - - -
Total Assets 30686 27476 24914 24627
Property/Plant/Equipment, Total - Net 1289 1238 975 975
Property/Plant/Equipment, Total - Gross - - - 1343
Accumulated Depreciation, Total - - - -368
Goodwill, Net - - - -
Intangibles, Net 200 216 234 254
Long Term Investments 155 201 239 371
Note Receivable - Long Term - - 341 31
Other Long Term Assets, Total - - 264 264
Other Assets, Total 8763 8253 8021 7274
Total Current Liabilities 2988 1944 1339 1568
Accounts Payable - - - 350
Payable/Accrued - - - -
Accrued Expenses - - - 296
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 79 80 60 62
Other Current liabilities, Total 2909 1864 1279 860
Total Liabilities 4029 2994 2195 2431
Total Long Term Debt 550 554 356 363
Long Term Debt - - - -
Capital Lease Obligations 550 554 356 363
Deferred Income Tax - - - -
Minority Interest - - - -
Other Liabilities, Total 491 496 500 500
Total Equity 26657 24482 22719 22196
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 66 66 66 66
Additional Paid-In Capital 12141 12063 12044 12029
Retained Earnings (Accumulated Deficit) 14299 12243 10512 10020
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 151 110 97 81
Total Liabilities & Shareholders' Equity 30686 27476 24914 24627
Total Common Shares Outstanding 65.23 65.4 65.49 65.43
Total Preferred Shares Outstanding - - - -
* In Millions of DKK (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GMAB Comments

Write your thoughts about Genmab AS
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email